ライフサイエンスコーパス: oral hypoglycemic agent

1 nts to drug dosing (eg, many antibiotics and oral hypoglycemic agents).

2 of sulfonylurea drugs, the most widely used oral hypoglycemic agents.

3 mic agents, 83 (80.58%) had low adherence to oral hypoglycemic agents.

4 d with T2D that can influence treatment with oral hypoglycemic agents.

5 occasions or patients taking any insulin or oral hypoglycemic agents 1 month or later after kidney t

6 3.9%), oral antiplatelet agents (13.3%), and oral hypoglycemic agents (10.7%).

7 th moderate periodontitis and healthy group: oral hypoglycemic agents (17.4% versus 16.8% versus 8.0%

8 rely required pharmacological treatment (17% oral hypoglycemic agents, 4% insulin).

9 herence to BP-lowering medications and using oral hypoglycemic agents, 83 (80.58%) had low adherence

10 iption of rosiglitazone, compared with other oral hypoglycemic agents, among 2393 long-term hemodialy

11 due to their widespread use as a second-line oral hypoglycemic agent and their relatively neutral car

12 and exercise therapy; staged introduction of oral hypoglycemic agents and finally insulin regimens of

13 were obtained from patients taking long-term oral hypoglycemic agents and were also exposed to 5 minu

14 casions: the first (control) while receiving oral hypoglycemic agents, and the second after the addit

15 % taking insulin-33% alone and 28% alongside oral hypoglycemic agents-and 79% having comorbid hyperte

16 eecham, Philadelphia, Pennsylvania) is a new oral hypoglycemic agent approved for the treatment of ty

17 The newer oral hypoglycemic agents are also in use and have mechan

18 Oral hypoglycemic agents are inhibitors of the ATP-sensi

19 with insulin monotherapy, is the addition of oral hypoglycemic agents associated with benefits (measu

20 Additionally, intake of oral hypoglycemic agents, calcium channel blockers (CCB)

21 6.4% filled a prescription for insulin or an oral hypoglycemic agent during the 120 days before admis

22 Patients receiving oral hypoglycemic agents for diabetes mellitus are at in

23 Basal insulin can be added to oral hypoglycemic agents (generally stopping sulfonylure

24 Pioglitazone is an oral hypoglycemic agent in the thiazolidinedione class.

25 atic alpha-amylase, a therapeutic target for oral hypoglycemic agents in type-2 diabetes.

26 from patients without long-term exposure to oral hypoglycemic agents is functionally protected by pr

27 d long-term inhibition of KATP channels with oral hypoglycemic agents may explain the excess cardiova

28 reater, age 18 years or older, taking 0 to 3 oral hypoglycemic agents (metformin, thiazolidinedione,

29 Rosiglitazone maleate is the second approved oral hypoglycemic agent of the thiazolidinedione class.

30 er were compared between the insulin and the oral hypoglycemic agent (OHA) groups.

31 tients with type 2 diabetes---7 treated with oral hypoglycemic agents (OHA R(X); mean [+/- SD] HbA(1c

32 or those not fasting), the use of insulin or oral hypoglycemic agents, or self-reported history.

33 In patients receiving long-term oral hypoglycemic agents (Oral Hypo+IPC), recovery of DF

34 Compared with patients prescribed other oral hypoglycemic agents, patients prescribed rosiglitaz

35 Troglitazone (Rezulin) is a promising new oral hypoglycemic agent recently approved by the Federal

36 /dL (>/= 7.0 mmol/L) >/= 30 days apart, (ii) oral hypoglycemic agent use for >/= 30 consecutive days,

37 Furthermore, IAA is a potent oral hypoglycemic agent with mitigating effects on metab

38 ere either taking no medication or taking an oral hypoglycemic agent (with or without insulin) were c

39 at myocardium from patients taking long-term oral hypoglycemic agents would be resistant to the prote